Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)

Method and clinical-monitoring paper for EasyM, a peripheral-blood clonotypic mass-spectrometry assay tracking serum M-protein for MRD in myeloma.

Clin Cancer ResPubMed 38170583